SCHEDULE: Janus Henderson Boosts Vaxcyte Stake to 11.4%
Beneficial Ownership Report
Janus Henderson Group plc has reported an 11.4% beneficial ownership stake in Vaxcyte, Inc. common stock as of June 30, 2025.
Summary
- Janus Henderson Group plc, a Jersey-based entity, reported beneficial ownership of 14,691,344 shares of Vaxcyte, Inc. common stock.
- This represents 11.4% of Vaxcyte, Inc.'s common stock class.
- The shares are held with shared voting power and shared dispositive power.
- The filing is an Amendment No. 7 to Schedule 13G.
- The ownership was acquired and is held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of beneficial ownership without explicit positive or negative implications within the filing itself.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional holding provides transparency regarding the ownership structure.
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date of Power of Attorney execution. |
| 2025-06-30 | Date of event which requires filing of this statement (reporting period end date for ownership). |
| 2025-08-14 | Date of filing signature. |
Keywords
Vaxcyte, Janus Henderson, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.